PTIR calculates the rates at which originally monomeric proteins are transformed into aggregates at various temperatures under initial-rate settings. Utilizing SMSLS for identical conditions generates ...

Researchers have identified a backup mechanism of protein quality control which prevents the toxic effects of protein aggregation in specific tissues when normal methods of molecular monitoring fail.

A team of researchers at Kumamoto University has uncovered a groundbreaking mechanism in the formation of harmful protein aggregates that lead to neurodegenerative diseases such as Parkinson's Disease ...

As antibiotic resistance continues to escalate globally, understanding how bacteria can evade treatment is more critical than ever. Some bacteria can enter dormant states, during which they are not ...

Yeast prions are increasingly recognised as pivotal agents in non-Mendelian inheritance, whereby protein conformations rather than nucleic acids dictate heritable traits. In Saccharomyces cerevisiae ...

Protein aggregation is typical of various neurodegenerative diseases such as Alzheimer's, Parkinson's and prion diseases such as Creutzfeld-Jakob disease. A research team has now used new in vitro and ...

Raghu R. Chivukula, MD, Ph.D., a physician-investigator in the Departments of Medicine & Surgery and the Center for Genomic Medicine at Massachusetts General Hospital and Harvard Medical School, is ...

A new study shows p62-mediated Mallory-Denk body formation is an adaptive, protective response to alcohol-induced liver ...

Researchers have used computational models to understand what drives the accumulation of alpha-synuclein protein, a key culprit in the development of Parkinson’s disease. The study, published today as ...

Northwestern Medicine scientists have discovered that an FDA-approved compound promotes neuroprotective effects in experimental models of Parkinson's disease. The compound, N-acetyl-L-leucine (NALL), ...

L-leucine, an FDA-approved compound, exerts neuroprotective effects in Parkinson’s disease models. By reducing alpha-synuclein aggregation and restoring dopamine signaling, NALL targets multiple ...